0
Comments
58
Views
The Intramuscular HPV Vaccination Market is expanding as governments, healthcare organizations, and pharmaceutical companies increase efforts to prevent human papillomavirus (HPV) infections and HPV-associated cancers. According to WiseGuyReports, the market was valued at approximately USD 6.6 billion in 2024 and is projected to reach USD 12.0 billion by 2035, representing a CAGR of approximately 5.6% from 2025 to 2035.
Increasing HPV prevalence, government immunization programs, greater public awareness, and improvements in vaccine technology are supporting market expansion. Expanding adolescent vaccination programs and increasing recognition of HPV's role in cervical and other cancers are creating additional opportunities.
